SINOPHARM(01099): China National Medicines Corporation(600511.SH) net profit attributable to parent company for the first three quarters was 1.492 billion yuan, an increase of 0.74% year-on-year.

SINOPHARM (01099) announced the performance of its subsidiary, China National Medicines Corporation (600511.SH), for the first three quarters of 2025. The company achieved a revenue of 39.381 billion yuan, a year-on-year increase of 3.56%. The net profit attributable to shareholders of the listed company was 1.492 billion yuan, a year-on-year increase of 0.74%. The non-recurring net profit was 1.47 billion yuan, a year-on-year decrease of 1.27%. The basic earnings per share were 1.9778 yuan.